HC Wainwright Issues Optimistic Estimate for Erasca Earnings

Erasca, Inc. (NASDAQ:ERAS) – HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for Erasca in a note issued to investors on Thursday, November 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.44) per share for the year, up from their prior forecast of ($0.48). The consensus estimate for Erasca’s current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Erasca’s Q4 2025 earnings at ($0.10) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($0.44) EPS and FY2028 earnings at ($0.26) EPS.

Several other research analysts have also weighed in on ERAS. Guggenheim lifted their price objective on Erasca from $3.00 to $5.00 and gave the stock a “buy” rating in a research report on Friday. Morgan Stanley restated an “equal weight” rating and issued a $2.00 target price (down previously from $4.00) on shares of Erasca in a report on Monday, August 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Erasca in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Erasca from a “sell” rating to a “hold” rating in a report on Sunday, September 21st. Finally, Bank of America reaffirmed an “underperform” rating and set a $1.00 price target (down previously from $4.00) on shares of Erasca in a research report on Wednesday, September 3rd. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $4.25.

Erasca Stock Performance

ERAS stock opened at $2.58 on Monday. The company has a market capitalization of $731.97 million, a P/E ratio of -5.73 and a beta of 1.19. Erasca has a 52-week low of $1.01 and a 52-week high of $3.30. The company has a fifty day moving average price of $2.18 and a 200-day moving average price of $1.71.

Erasca (NASDAQ:ERAS) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.11).

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ERAS. Frazier Life Sciences Management L.P. boosted its holdings in Erasca by 16.4% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 22,575,851 shares of the company’s stock valued at $30,929,000 after acquiring an additional 3,184,164 shares during the period. VR Adviser LLC increased its stake in shares of Erasca by 10.1% in the second quarter. VR Adviser LLC now owns 17,857,083 shares of the company’s stock worth $22,678,000 after buying an additional 1,640,867 shares during the period. Affinity Asset Advisors LLC increased its position in shares of Erasca by 33.7% in the first quarter. Affinity Asset Advisors LLC now owns 3,341,519 shares of the company’s stock valued at $4,578,000 after acquiring an additional 842,088 shares during the period. T. Rowe Price Investment Management Inc. raised its stake in shares of Erasca by 3.5% during the first quarter. T. Rowe Price Investment Management Inc. now owns 17,292,164 shares of the company’s stock valued at $23,691,000 after acquiring an additional 581,817 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in shares of Erasca during the first quarter worth about $663,000. Hedge funds and other institutional investors own 67.78% of the company’s stock.

About Erasca

Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.